Sequential Doxorubicin and Docetaxel as First-Line Treatment in Metastatic Breast Cancer: A GEICAM-9801 Phase II Study

被引：0
|
作者：
E. Alba
N. Ribelles
A. Antón
R. Pérez-Carrión
J.M. López-Vega
M. Llanos
A. Pelegri
J. Florián
M. Menéndez
M.J. Godes
机构：
[1] Hospital Clínico Universitario,
[2] Hospital Miguel Servet,undefined
[3] Hospital de la Princesa,undefined
[4] Hospital Valdecilla,undefined
[5] Hospital Universitario de Canarias,undefined
[6] Hospital Sant Joan de Reus,undefined
[7] Hospital Barbastro,undefined
[8] C Hospitalario de Santiago,undefined
[9] Hospital General Universitario,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 77卷
关键词：
first-line chemotherapy; metastatic breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. To evaluate the efficacy and the toxicity profile of the sequential administration of doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC).
引用
收藏
页码：1 / 8
页数：7
相关论文
共 50 条
  • [21] A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer
    Smitha Subramanyan
    Martin D. Abeloff
    Stephen E. Bond
    Nancy E. Davidson
    John H. Fetting
    Gary B. Gordon
    M. John Kennedy
    Cancer Chemotherapy and Pharmacology, 1999, 43 : 497 - 502
  • [22] A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer
    Perez, EA
    Geeraerts, L
    Suman, VJ
    Adjei, AA
    Baron, AT
    Hatfield, AK
    Maihle, N
    Michalak, JC
    Kuross, SA
    Kugler, JW
    Lafky, JM
    Ingle, JN
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1225 - 1235
  • [23] First-line chemotherapy of advanced or metastatic breast cancer (MBC) with docetaxel and doxorubicin in Indonesia: results from A phase II trial
    Abdulmuthalib
    Darwis, Idral
    Prayogo, Nugroho
    Sutjipto
    MEDICAL JOURNAL OF INDONESIA, 2005, 14 (01) : 20 - 25
  • [24] Non-pegylated liposomal doxorubicin and docetaxel as first-line treatment in metastatic breast cancer.
    Heilmann, V
    Eggemann, H
    Sommer, H
    Heinrich, G
    Blohmer, JU
    Mallmann, PK
    Krabisch, P
    Klare, P
    Schilling, J
    Kittel, K
    Elling, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 66S - 66S
  • [25] Phase II multicenter sequential study of docetaxel (T) and epirubicin (E) followed by docetaxel (T) and capecitabine (X) as first-line treatment of advanced or metastatic breast cancer (MBC).
    Ramos, M
    Casal, J
    Galán, A
    Almanza, C
    León, L
    Amenedo, M
    Gonzalez, A
    Huidobro, G
    Giner, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 54S - 54S
  • [26] A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer
    Venturini, M.
    Bighin, C.
    Puglisi, F.
    Olmeo, N.
    Aitini, E.
    Colucci, G.
    Garrone, O.
    Paccagnella, A.
    Marini, G.
    Crino, L.
    Mansutti, M.
    Baconnet, B.
    Barbato, A.
    Del Mastro, L.
    BREAST, 2010, 19 (05): : 333 - 338
  • [27] Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC)
    Mel, J. R., Sr.
    Ramos, M.
    Cueva, J.
    Castellanos, J.
    Almanza, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
    Musolino, A.
    Bisagni, G.
    De Matteis, A.
    Nuzzo, F.
    Ardizzoni, A.
    Crino, L.
    Gamucci, T.
    Passalacqua, R.
    Gnoni, R.
    Boni, C.
    CANCER RESEARCH, 2010, 70
  • [29] A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer
    Shamseddine, Ali I.
    Otrock, Zaher K.
    Khalifeh, Mohamad J.
    Yassine, Hanan R.
    Charafeddine, Maya
    Abdel-Khalek, Zeina
    Chehal, Aref
    Bitar, Nizar
    Jalloul, Rahif
    Dheiny, Moussa
    Dandashi, Azzam
    Wehbeh, Mahmoud
    El-Saghir, Nagi S.
    ONCOLOGY, 2006, 70 (05) : 330 - 338
  • [30] A phase II study of bi-weekly docetaxel as first-line therapy for metastatic breast cancer.
    Durna, L. N.
    Yeon, C. H.
    Bosserman, L. D.
    Allison, M.
    Hu, E.
    Tchekmedyian, N. S.
    Srivastava, N.
    Ngo, D.
    Lin, L. S.
    Classen, S.
    Slamon, D. J.
    Pegram, M. D.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S280 - S280
12345